Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;15(2):93-99.

Management Approaches to Hepatitis B Virus Vaccination Nonresponse

Beshoy Yanny  1   2 , Peter Konyn  1   2 , Lisa M Najarian  1   2 , Amanda Mitry  1   2 , Sammy Saab  1   2
Affiliations

Management Approaches to Hepatitis B Virus Vaccination Nonresponse

Beshoy Yanny et al. Gastroenterol Hepatol (N Y). 2019 Feb.

Abstract

Background: Despite the availability of hepatitis B virus (HBV) vaccination, HBV remains a cause of significant morbidity and mortality around the world. Immunologic response and the development of immunity to the HBV vaccine vary significantly among patients. Multiple studies have looked at patients who are at risk of nonresponse and have offered their own approaches to patients who do not respond. This article reviews the best approaches to HBV vaccine nonresponse. Methods: We searched the PubMed database for all articles on HBV vaccination response from 1981 to January 2018. Recommended and tested approaches to nonresponse were identified. Results: A total of 71 adequate-quality studies with 2354 patients were identified. Repeat vaccination with the same dose increased immunologic seroconversion in 85.7% of patients who previously reported nonresponse and in over 80% of patients with end-stage renal disease, HIV infection, hepatitis C virus (HCV) infection, advanced age, hypoalbuminemia, liver cirrhosis, and hemodialysis (HD) dependence. Patients with inflammatory bowel disease, celiac disease, and diabetes had a milder response (67.5%). Increasing the vaccination dose to 40 µg improved seroconversion in HIV-infected, HCV-infected, and HD patients of initial nonresponse. The use of a subcutaneous injection route increased response by 12% in patients infected with HIV. Conclusion: Patients not responding to an initial vaccine series and not actively infected with HBV benefited from reimmunization by repeating the vaccine series or receiving a single-dose vaccine booster. Although the overall response rate was approximately 90% of previous nonresponders, the rate varied among the populations studied.

Keywords: Hepatitis B virus vaccine; hepatitis immunity; immunologic response.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant conflicts of interest to disclose.

Figures

Figure.
Figure.
A proposed approach to at-risk populations.
See this image and copyright information in PMC

References

    1. Walayat S, Ahmed Z, Martin D, Puli S, Cashman M, Dhillon S. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World J Hepatol. 2015;7(24):2503–2509. - PMC - PubMed
    1. van den Berg R, van Hoogstraten I, van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev. 2009;11(3):157–164. - PubMed
    1. Jiang HY, Wang SY, Deng M et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and metaanalysis. Vaccine. 2017;35(20):2633–2641. - PubMed
    1. Marín AC, Gisbert JP, Chaparro M. Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. World J Gastroenterol. 2015;21(40):11273–11281. - PMC - PubMed
    1. Sempere L, Almenta I, Barrenengoa J et al. Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. Vaccine. 2013;31(30):3065–3071. - PubMed

LinkOut - more resources